Boehringer Ingelheim Plans 10 Drug Launches by 2016

Boehringer Ingelheim laid out an ambitious agenda for itself over the next two years, planning more than 10 new launches of drugs in eight disease indications by 2016 for diabetes, COPD, asthma, lung cancer, idiopathic pulmonary fibrosis, a rare form of leukemia, and the treatment and prevention of deep venous thrombosis and pulmonary embolism. 
Genetic Engineering & Biotechnology News